Accenture Again Positioned as a Leader in IDC MarketScape on Life Science Drug Safety Services
June 20 2017 - 9:59AM
Business Wire
Accenture (NYSE:ACN) has been positioned as a “Leader” in IDC
Health Insights’ recently published report, “IDC MarketScape:
Worldwide Life Sciences Drug Safety Services 2017 Vendor
Assessment.” 1 This is the second consecutive time
Accenture has been named a Leader in the vendor assessment report,
which is derived from qualitative and quantitative metrics as well
as end-user feedback of drug safety service providers in the life
sciences industry through the IDC MarketScape model. Click
here for a link to the 2017 report.
The report notes that relative to other vendors discussed in
this document and based on feedback from customer references,
Accenture received high marks as an industry thought leader as well
as a knowledgeable, unbiased, high-quality service provider and
strategic partner, adjusting resources as needed, asking the right
questions, and capably filling project knowledge gaps. IDC Health
Insights assessed eight drug safety service providers for this
report, which is designed to evaluate the characteristics of each
firm.
In naming Accenture as a leader, the report’s author, Alan S.
Louie, PhD, research director, of IDC Health Insights’ Life Science
R&D Strategy and Technology research, said, "The drug safety
services space within the life sciences industry has matured and is
increasingly a mainstream contributor to helping to advance the
industry forward. Unsustainable growth in drug safety BPO and
evolving drug safety regulatory compliance requirements are forcing
leading service providers in the space to continue to innovate, and
IDC expects that leading service providers like Accenture in the
space will be those vendors that continue to seek better and more
efficient ways to deliver drug safety services looking
forward."
Kevin Julian, a senior managing director leading the Accenture
Life Sciences practice in North America said, "We believe
Accenture’s positioning as a leader for a second time in this
report is verification of the results we deliver every day to our
life sciences’ clients who entrust us with drug safety services. We
are focused on helping our clients pivot to the patient and improve
patient safety by using innovative technologies to drive
efficiency, help enable automation and advanced analytics, while
maintaining quality and compliance.”
IDC Health Insights focuses on the following key criteria to
define excellence in drug safety services:
- Service focus experience (i.e., BPO, IT
services, or strategic consulting drug safety services)
- Breadth of drug safety service
offerings
- Strength and diversity of resources and
infrastructure supporting services deliver
- Project experience in the life science
drug safety service outsourcing market
- Strength of project leaders and their
teams
- Quality of work and customer
satisfaction
- Current and planned drug safety
investments
- Proportion of drug safety efforts where
intellectual property is involved or generated
The IDC MarketScape divides potential key strategy measures for
success into two primary categories: capabilities and strategies.
IDC Health Insights specifically noted in this report, “Building on
an aggressive growth and acquisition strategy, Accenture has
diversified significantly beyond its traditional big pharma focus
and has grown its presence among emerging and mid-tier life science
companies in recent years.”
This latest report follows an April 2017 IDC Perspective, “How
Machine Learning and Cognitive Computing are Delivering Near-Term
Value and ROI in Life Science R&D Today.” In this IDC
Perspective, Accenture’s PV First - a cloud-based platform for
pharmacovigilance - was cited: “With ongoing machine learning and
continuing automation of new drug safety analytics insights, PV
First should continue to mitigate the level of drug safety
resources needed to maintain full drug safety regulatory
compliance.”
About Accenture
Accenture is a leading global professional services company,
providing a broad range of services and solutions in strategy,
consulting, digital, technology and operations. Combining unmatched
experience and specialized skills across more than 40 industries
and all business functions – underpinned by the world’s largest
delivery network – Accenture works at the intersection of business
and technology to help clients improve their performance and create
sustainable value for their stakeholders. With approximately
401,000 people serving clients in more than 120 countries,
Accenture drives innovation to improve the way the world works and
lives. Visit us at www.accenture.com.
About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an
overview of the competitive fitness of ICT (information and
communications technology) suppliers in a given market. The
research methodology utilizes a rigorous scoring methodology based
on both qualitative and quantitative criteria that results in a
single graphical illustration of each vendor’s position within a
given market. IDC MarketScape provides a clear framework in which
the product and service offerings, capabilities and strategies, and
current and future market success factors of IT and
telecommunications vendors can be meaningfully compared. The
framework also provides technology buyers with a 360-degree
assessment of the strengths and weaknesses of current and
prospective vendors.
1 IDC MarketScape: Worldwide Life Science Drug Safety
Services 2017 Vendor Assessment, doc #US42595616, June 2017.2 How
Machine Learning and Cognitive Computing are Delivering Near-Term
Value and ROI in Life Science R&D Today, doc #US42491417, April
2017
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170620005949/en/
AccentureCam Granstra, + 1 312 693
5992cameria.l.granstra@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Sep 2023 to Sep 2024